Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)--Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group

Dubé, Michael P.; Stein, James H.; Aberg, Judith A.; Fichtenbaum, Carl J.; Gerber, John C.; Tashima, Karen T.; Keith Henry, W.; Currier, Judith S.; Sprecher, Dennis; Glesby, Marshall J.
September 2003
Clinical Infectious Diseases;9/1/2003, Vol. 37 Issue 5, p613
Academic Journal
Focuses on recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group for the evaluation and management of dyslipidemia in HIV infected adults receiving antiretroviral therapy. Information about dyslipidemia; Details of the recommendations.


Related Articles

  • Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. del Amo, J.; del Romero, J.; Barrasa, A.; Pérez-Hoyos, S.; Rodríguez, C.; Díez, M.; Garcí, S.; Soriano, V.; Castilla, J. // Sexually Transmitted Infections;Aug2002, Vol. 78 Issue 4, p255 

    Objective: To study HIV progression from seroconversion over a 15 year period and measure the population effectiveness of highly active antiretroviral therapy (HAART). Methods: A cohort study of people with well documented dates of seroconversion. Cumulative risk of AIDS and death were...

  • Nelfinavir: A Review of its Therapeutic Efficacy in HIV Infection. Jarvis, B.; Faulds, D. // Drugs;Jul1998, Vol. 56 Issue 1, p147 

    Nelfinavir is a selective inhibitor of HIV protease, the enzyme responsible for post-translational processing of HIV propeptides. In the presence of the drug, immature, noninfectious virus particles are produced. Nelfinavir in combination with nucleoside reverse transcriptase inhibitors,...

  • HIV wages war on 'miracle' drugs. Cohen, Philip // New Scientist;8/17/2002, Vol. 175 Issue 2356, p22 

    Reports the need to develop drugs to combat resistance to HIV virus in the U.S. Details on the screening of HIV patients for resistance; Efficacy of antiviral drugs against AIDS; Side effects of antiviral agents.

  • ritonavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p193 

    An encyclopedia entry for ritonavir, which is an HIV protease inhibitor that works by interfering with the reproductive cycle of HIV, is presented.

  • Significant Challenges Facing HIV Practitioners. Bartlett, John G. // Journal of Infectious Diseases;5/15/2008 Supplement 3, pS250 

    The article discusses various reports published within the issue including one by Martin S. Hirsch on the latest information about when to start antiretroviral therapy during chronic infection and another by Joseph J. Ephron on the issues related to treatment-experienced patients.

  • Prevalence of different HIV-1 subtypes in an urban clinic in Madrid. J.C. Martín // Sexually Transmitted Infections;Feb2002, Vol. 78 Issue 1, p1 

    The introduction of non-B HIV-1 variants into Western Europe and North America is of great concern since diagnostic tools and drugs are mainly optimised for targeting HIV-1 subtype B viruses. Madrid is an endemic area for HIV, and either the final destination or transient location for many...

  • WHO: Earlier ART could prevent 3 million HIV deaths. Cox, Amber; Schoen, John; Stott, Bob; Todak, Alexandra // Infectious Disease News;Jul2013, Vol. 26 Issue 7, p32 

    The article reports on the issuance of new human immunodeficiency virus (HIV) guidelines by the World Health Organization (WHO) which recommend the early administration of antiretroviral therapy (ART) as well as its provision to adult HIV patients whose CD4 cell count drops to 500 cells/mm³.

  • Suitable Monitoring Approaches to Antiretroviral Therapy in Resource-Poor Settings: Setting the Research Agenda. Kent, David M.; McGrath, Donnie; Loannidis, John P. A.; Bennish, Michael L. // Clinical Infectious Diseases;7/1/2003 Supplement 1, Vol. 37, pS13 

    The delivery of antiretroviral therapy in the developing world requires guidelines for the appropriate monitoring of therapy, including monitoring for treatment effectiveness and treatment failure, drug toxicities, adherence to therapy, and the emergence of resistant organisms. Guidelines...

  • CD8[sup +] Cell-Derived Anti-Human Immunodeficiency Virus Inhibitory Factor. Baker, Edward // Journal of Infectious Diseases;5/15/99 Supplement 3, Vol. 179, pS485 

    Discusses the role and mechanism of the soluble factor CD8[sup +] cell antiviral factor (CAF) in suppressing HIV replication in infected cells. Control of replication in a noncytotoxic manner; Interruption of the ability of Tat or host cellular factors to interact with the HIV long terminal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics